Tempus AI Publishes XF+ Assay Study Results in Journal of Molecular Diagnostics
Tempus AI Announces Publication Of Its Study 'Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy' In The Journal of Molecular Diagnostics
BTIG Maintains Tempus AI(TEM.US) With Buy Rating, Maintains Target Price $60
Tempus AI Inc Class A Call Volume Above Normal and Directionally Bullish
Analysts Split on High-Stakes 'Call Option' for Tempus AI Stock (TEM)
Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform
Will the US Stock Market's Rebound Ignite Your Next Trade?
Why Tempus AI Inc. (TEM) Soared Last Week
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, IRhythm Technologies and SOPHiA GENETICS
TD Cowen Maintains Tempus AI(TEM.US) With Buy Rating, Cuts Target Price to $62
Press Release: Tempus to Report First Quarter 2025 Financial Results on May 6
Beyond The Numbers: 9 Analysts Discuss Tempus AI Stock
TD Cowen Remains a Buy on Tempus AI, Inc. Class A (TEM)
Bank of America warns about the "tariff storm" in the Software industry, with subscription models becoming a safe haven.
Bank of America recently released an in-depth Research Report on the Software Industry, focusing on the impact of macroeconomic uncertainty on software companies.
Needham Maintains Tempus AI(TEM.US) With Buy Rating, Maintains Target Price $70
Tempus AI, Inc. (TEM): A Bull Case Theory
Tempus AI Options Spot-On: On April 23rd, 66,640 Contracts Were Traded, With 234.89K Open Interest
Sector Update: Health Care Stocks Edge Up Late Afternoon
Tempus AI Stock Is Ripping Higher Wednesday: What's Fueling The Move?